Cargando…

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess

Detalles Bibliográficos
Autores principales:	Pivonello, Rosario, Ferrigno, Rosario, Isidori, Andrea M, Biller, Beverly M K, Grossman, Ashley B, Colao, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7282791/ https://www.ncbi.nlm.nih.gov/pubmed/32531251 http://dx.doi.org/10.1016/S2213-8587(20)30215-1

Ejemplares similares

Glucocorticoid excess and COVID-19 disease
por: Guarnotta, Valentina, et al.
Publicado: (2020)

Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022)

Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials
por: Pivonello, Rosario, et al.
Publicado: (2020)

The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications
por: Isidori, Andrea M., et al.
Publicado: (2015)

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes
por: Fleseriu, Maria, et al.
Publicado: (2022)

Approach to patients with pseudo-Cushing’s states
por: Scaroni, Carla, et al.
Publicado: (2019)

Susceptibility and characteristics of infections in patients with glucocorticoid excess or insufficiency: the ICARO tool
por: Minnetti, Marianna, et al.
Publicado: (2022)

A New Clinical Model to Estimate the Pre-Test Probability of Cushing’s Syndrome: The Cushing Score
por: Parasiliti-Caprino, Mirko, et al.
Publicado: (2021)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

Paediatric Cushing’s disease: Epidemiology, pathogenesis, clinical management and outcome
por: Ferrigno, Rosario, et al.
Publicado: (2021)

Use of glucocorticoids in patients with adrenal insufficiency and COVID-19 infection
por: Isidori, Andrea M, et al.
Publicado: (2020)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency
por: Simeoli, Chiara, et al.
Publicado: (2019)

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
por: Pivonello, Rosario, et al.
Publicado: (2022)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
por: Newell-Price, John, et al.
Publicado: (2019)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

The treatment with pasireotide in Cushing’s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center
por: Simeoli, C., et al.
Publicado: (2019)

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
por: He, Xin, et al.
Publicado: (2022)

Imbalanced cortisol concentrations in glycogen storage disease type I: evidence for a possible link between endocrine regulation and metabolic derangement
por: Rossi, Alessandro, et al.
Publicado: (2020)

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Approach to the Patient With Prolactinoma
por: Auriemma, Renata S, et al.
Publicado: (2023)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”
por: Pivonello, Rosario, et al.
Publicado: (2019)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

Testis-Specific Genes Deregulation in the Testis of COVID-19 Patients: A Potential Driver of Spermatogenesis Disruption?
por: Pivonello, Rosario, et al.
Publicado: (2022)

Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations
por: Colao, Annamaria, et al.
Publicado: (2013)

Metformin and Bone Metabolism in Endogenous Glucocorticoid Excess: An Exploratory Study
por: Vogel, Frederick, et al.
Publicado: (2021)

Metabolic effects of prolactin
por: Pirchio, Rosa, et al.
Publicado: (2022)

Smoke, alcohol and drug addiction and female fertility
por: de Angelis, Cristina, et al.
Publicado: (2020)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0id9775fb3vgmdh3c3bfca0mtt